Best of ASCO - 2014 Annual Meeting

 

Welcome

Chronic Leukemia—CML and Hairy Cell

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs).

Michael J. Mauro

TPS7070

A novel anti-CD19 chimeric T cell therapy platform ET019002 was safe and effective in inducing CR in blast crisis of CML: A case study.

Pengcheng He

e18540

Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial.

Jorge E. Cortes

7051

CML patients presenting with priapism: Is there any disparity in outcome?

Aditya Jandial

e18545

Effect of secure clinical messaging on chemotherapy adherence.

Sarah McLarty

e18542

ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).

Timothy P. Hughes

7005

Frontline flumatinib versus imatinib in patients with chronic myeloid leukemia in chronic phase: Results from the China randomized phase III study.

Zhang Li

7004

Molecular prediction of chronic myeloid leukemia risk and resistance to imatinib.

Radmila Jankovic

e18543

Outcome of CML patients with de novo bleeding complications: Do they behave differently?

Rajeev Sandal

e18546

Pooled safety summary for patients treated with the CD22-directed cytotoxin moxetumomab pasudotox-tdfk.

Robert J. Kreitman

7014

Primary results of the phase 4 BYOND study of bosutinib (BOS) for pretreated chronic phase (CP) chronic myeloid leukemia (CML).

Carlo Gambacorti-Passerini

7012

Randomized phase II study of cladribine with simultaneous or delayed rituximab in patients with untreated hairy cell leukemia.

Dai Chihara

7003

The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.

Mahran Shoukier

e18539

Treatment-free remission (TFR) following frontline (1L) nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): 192-week data from the ENESTfreedom study.

Francis J. Giles

7013

Update on lower-dose dasatinib 50 mg daily as frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP).

Kiran Naqvi

7052